Clinical trial / 2014
Phyllanthus emblica extract showed antiplatelet activity alone and combined with clopidogrel or ecosprin in type II diabetic patients.
A randomized open-label crossover study evaluated 10 type II diabetic patients given single and multiple (10-day) doses of 500 mg Phyllanthus emblica extract, 75 mg clopidogrel, 75 mg ecosprin, or combinations. Statistically significant decreases in platelet aggregation compared to baseline were observed after single and multiple dose administration across all three treatments and combinations. Bleeding and clotting times were prolonged with all treatments compared to baseline, and all treatments were well tolerated.
- Study type
- Randomized open-label crossover trial
- Who was studied
- 10 type II diabetic patients
- What was measured
- Platelet aggregation, bleeding time, and clotting time
THE PAPER
Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus.
Fatima N, Pingali U, Muralidhar N. Phytomedicine, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.